ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...

Shares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after ...

The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

A new vaccine that boosts immunity against tuberculosis (TB) has been shown to be effective in pioneering pre-clinical trials.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...

Researchers from Australia have developed a groundbreaking mRNA vaccine against tuberculosis (TB), showing promising results in pre-clinical mouse trials. This innovative vaccine could outperform the ...

ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...

UroGen Pharma has opened another front in its attack on bladder cancer, paying IconOVir Bio $4 million in stock for an early-phase oncolytic virus that could work like a turbocharged Bacillus Calmette ...

A beverage company thinks like a startup to maintain a closer connection with its customers. That’s the word from a recent episode of MIT’s and BCG’s Me, Myself, and AI, which featured Ronald den ...

Coding assistance and completion tools saved developers around 4 million hours last year, the retailer said during an ...

Research by BCG shows that the most common strategy is to carry out one-off cost optimisation initiatives at set intervals. But a minority of the leaders surveyed (26 per cent) see cost management ...